Sandoz has confirmed the
acceptance by the US FDA of
a regulatory submission for a
proposed biosimilar pegfilgrastim,
with the reference product being
Amgen’s Neulasta - a recombinant
human granulocyte colony-stimulating
factor.
It’s the third Sandoz biosimilar
filing in the US, with the company
presenting three clinical trials
which “demonstrate that the
proposed biosimilar is highly similar
to the reference product”.
Sandoz says it has another seven
biosimilars in the wings planned for
filing over the next three years.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Nov 15
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.